1. Participants in the ACTIV-3 study were treated with either a study drug (bamlanivimab) plus current standard of care (Remdesivir), or with placebo plus current standard of care (Remdesivir).

### Key Clinical Trials

Lilly is studying neutralizing antibodies for prevention and treatment of COVID-19 in mild to moderate patients.

The timing for data disclosure from these trials is highly dependent on patient enrollment and any interim efficacy and safety data we may see.

#### BLAZE-1

**Stage of COVID-19 Illness**: Mild to Moderate  
**Drug**: bamlanivimab and bamlanivimab + etesevimab  
**Phase(s)**: Phase 2  
**Trial Type**: Randomized, double-blind, placebo-controlled trial  
**Goal(s)**: Reduce hospitalization or death and viral load  
**Participants**: Over 800 residents and staff of skilled nursing and assisted living facilities who are at risk of exposure due to a positive case of COVID-19 in the facility  
**Location**: U.S.  
**Study Status**: Ongoing  
**Sponsor Collaborators**: Lilly  
**Contribute**: Lilly, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Operation Warp Speed, Lilly and other contributors

#### BLAZE-2

**Stage of COVID-19 Illness**: Mild to Moderate  
**Drug**: Bamlanivimab  
**Phase(s)**: Phase 3  
**Trial Type**: Randomized, double-blind, placebo-controlled trial  
**Goal(s)**: Prevent SARS-CoV-2 infection and COVID-19  
**Participants**: Over 2,400 residents and staff of skilled nursing and assisted living facilities who are at risk of exposure due to a positive case of COVID-19 in the facility  
**Location**: U.S.  
**Study Status**: Ongoing  
**Sponsor Collaborators**: Lilly, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Operation Warp Speed, Lilly and other contributors

#### ACTIV-2

**Stage of COVID-19 Illness**: Hospitalized  
**Drug**: Bamlanivimab  
**Phase(s)**: Phase 2/3  
**Trial Type**: Multicenter, adaptive, randomized, blinded controlled trials  
**Goal(s)**: Prevent hospitalization or death  
**Participants**: Several hundred international clinical sites. See a full list at clinicaltrials.gov.  
**Location**: Several hundred international clinical sites. See a full list at clinicaltrials.gov.  
**Study Status**: Ongoing  
**Sponsor Collaborators**: Lilly and other contributors

#### ACTIV-3

**Stage of COVID-19 Illness**: Hospitalized  
**Drug**: Bamlanivimab  
**Phase(s)**: Phase 2/3  
**Trial Type**: Multicenter, adaptive, randomized, blinded controlled trial  
**Goal(s)**: Prevent hospitalization or death  
**Participants**: Several hundred international clinical sites. See a full list at clinicaltrials.gov.  
**Location**: Several hundred international clinical sites. See a full list at clinicaltrials.gov.  
**Study Status**: Ongoing  
**Sponsor Collaborators**: Lilly and other contributors

---

For more information, refer to these listings on clinicaltrials.gov or visit lilly.com